Clinical lead opportunities The company is focused on intraoperative OCT with AI enhancements, presenting a strong fit for hospitals and surgical centers seeking real-time imaging to improve cancer surgery outcomes. Target surgical departments such as breast, oncology, and head and neck surgeons who perform margin assessments.

Strategic partnerships Active collaboration with the University of Toronto on scalable AI infrastructure signals an openness to co-development and academic partnerships. Approach research institutions, teaching hospitals, and innovation labs for joint pilots or funded studies to validate Claire OCT+AI in real-world settings.

Public market visibility Recent announcements around product unveilings Claire OCT+AI and active participation in industry conferences indicate ongoing marketing momentum. Leverage event calendars and investor engagement opportunities to align clinical demonstrations with prospective hospital procurement cycles.

Global footprint With Toronto origins and Dallas headquarters, the company maintains cross-border operations and commercial-stage status. Pursue multinational hospital networks and distributors in the US and Canada to accelerate scale, supported by a strong healthcare IT and HIPAA-compliant stance.

Financial runway Revenue range and recent modest funding suggest space for expanded deployments and tiered pricing models. Propose value-based implementations, bundled OCT+AI solutions, and financing options to accelerate adoption in mid-market and regional health systems.